Skip Nav
Clinical Guidelines Portal
- What's New in the Guidelines
- Guidelines Panel Members
- Financial Disclosure
- Introduction
- Lessons From Clinical Trials of Antiretroviral Interventions to Reduce Perinatal Transmission of HIV
- Preconception Counseling and Care for HIV-Infected Women of Childbearing Age
- Antepartum Care
- Special Considerations Regarding the Use of Antiretroviral Drugs by HIV-Infected Pregnant Women and Their Infants
- Antiretroviral Drug Resistance and Resistance Testing in Pregnancy
- Intrapartum Care
- Postpartum Care
- Appendix A: Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
- Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Amprenavir (Agenerase, APV)
- Atazanavir (Reyataz, ATV)
- Darunavir (Prezista, DRV)
- Fosamprenavir (Lexiva, FPV)
- Indinavir (Crixivan, IDV)
- Lopinavir + Ritonavir (Kaletra, LPV/r)
- Nelfinavir (Viracept, NFV)
- Ritonavir (Norvir, RTV)
- Saquinavir (Invirase [Hard Gel Capsule], SQV)
- Tipranavir (Aptivus, TPV)
- Entry Inhibitors
- Integrase Inhibitors
- Antiretroviral Pregnancy Registry
- Appendix B: Acronyms
html message